Technology and Knowledge Diffusion

Slideshow: Innovation and the COVID-19 Response

On 26 November 2021 the new research report about the role that intellectual property played in the development, manufacturing, and global distribution of COVID-19 vaccines and therapeutics was launched in Geneva. The report was co-authored by Innovation Council’s very own Jennifer Brant, and Prof. Mark Schultz.

The report is available here, along with a slideshow of the research project.

View Post

Unprecedented – The Rapid Innovation Response to COVID-19 and the Role of Intellectual Property

Jennifer Brant, Director of Innovation Council, will present a recent research report that she co-authored about the constructive role played by IP rights in the rapid development and manufacturing of COVID-19 solutions. Jetane Charsley, Head of NIPMO, will host the event and lead a moderated discussion.

Tuesday, May 10 / 01:00 PM Johannesburg (CET)

Click here to register for this event.

View Post

IP Training Programs for Innovators of the Future

Every April 26, the global IP community marks World Intellectual Property Day to celebrate the role that intellectual property (IP) rights play in encouraging innovation and creativity. This year the theme of World Intellectual Property Day is “IP and Youth: Innovating for a Better Future” and celebrates youth-led ingenuity.

Across the globe, young people are stepping up to meet innovation challenges, using their energy and ingenuity, curiosity, and creativity to steer a course towards a better future. Knowledge about how to secure and manage intellectual property rights can accelerate their efforts. Therefore, Innovation Council has created an infographic featuring IP training programs dedicated to the innovators of the future.

 

 

 

View Post

A Covid vaccine breakthrough bypasses the stale debate on patent waivers 

Heated debates have taken place at the WTO TRIPS Council over Covid-19 vaccine patents and IP rights, with ongoing discussions still taking place among diplomats from the US, India, South Africa, and the EU. For vaccine researchers, manufacturers, and public experts, though, the focus may have moved on some time ago, says Alan Beattie in a new “trade secrets” posting for the FT. Governments seem also to be shifting focus to emphasize practical efforts to extend  manufacturing and distribution capacity globally; by way of example, the EU recently announced a €1bn contribution to finance the German company BioNTech to set up a mobile vaccine manufacturing plant in Africa assembled from kits.

Read the full story. 

View Post

Slideshow: Extending Bio-manufacturing Networks in Africa and IP and Covid

This slideshow presents key messages from the recent Innovation Council – Bobab online discussion about extending bio-manufacturing networks in emerging regions, notably Africa. The discussion on February 8th featured Prof. Mark Schultz of the University of Akron School of Law, Anissa Boumlic of Merck Life Science, and Simon Agwale of the African Vaccine Manufacturing Initiative. Click here for the video of the event, and click here to review a transcript of the event.

Read the full story.

View Post

BioNTech to supply modular vaccine plants to African countries

The German company BioNTech announced on February 16th its plans to supply modular plants to make mRNA vaccines to Rwanda, Senegal and, potentially, South Africa. This announcement came ahead of a Europe-Africa summit at which increasing vaccine production in Africa is expected to be a vital topic of discussion. Not only would BioNTech be responsible for the delivery and installation of the modules, but the company said it was prepared to transfer know-how to local partners to enable them to operate independently.

While it had been previously stated that voluntary technology transfers had so far been limited during the pandemic, this was contradicted by research published end-2021, which can be found in an online report

Read the full story. 

 

View Post

Bobab discussion about bio-manufacturing in emerging regions

The Innovation Council and Bobab organised a discussion on expanding BioManufacturing production capacity in emerging regions. Biologics, a category of pharmaceuticals which includes products such as vaccines and monoclonal antibody treatments, are quickly becoming among the most important medical products in the world. By combining enabling government policies and technology transfer between innovators and their global partners, it will be possible to improve availability of biologics, increase health security, and enhance scientific and industrial capacity in developing countries.

Click here to see the transcript.

View Post

University to help health practitioners find innovative solutions to healthcare challenges

The growing challenges on healthcare systems around the world has inspired researchers at the University of Bath to devise an online course to help healthcare practitioners spot opportunities for innovation in their organisations, and put ideas into practise.

The free online course, known as a MOOC (Massive Open Online Course) takes four weeks to complete and is devised by the School of Management’s Centre for Healthcare Innovation and Improvement (CHI²), along with the West of England Academic Health Science Network (AHSN).

Read the full story.

View Post

What South Korea’s vaccine industry success teaches us about global trade policy

Jennifer Brant of the Innovation Council co-authored an article with Godfrey Firth for the World Economic Forum that uses the example of South Korea to show that tariff, trade facilitation and regulatory harmonisation measures can facilitate the global response to health crises such as COVID-19.

Read the full story.

View Post